07:55–08:55 Cubex A1 + A2 |
Breakfast & INDUSTRY SYMPOSIUM |
09:00–10:00 Cubex A1 + A2 |
PANEL DISCUSSION: How do we ensure treatments are available to everyone with IgAN? Moderators: Heather Reich, Hernan Trimarchi Panellists: Irene de Lourdes Noronha, Vivekanand Jha, Adrian Liew, Bonnie Schneider |
10:00–11:00 Cubex A1 + A2 |
PLENARY SESSION 4: IgAN Pathogenesis 2 Chairs: Renato Monteiro, Xueqing Yu Katherine Bull: Understanding the glomerular response to IgA deposition Heather Reich: Immune cells in the kidney are they important in IgAN? Dana Rizk: The role of complement in IgAN (the glomerulus and beyond) |
11:00–11:30 |
Coffee break |
11:30–11:50 Cubex A1 + A2 |
PLENARY SESSION 5: IIGANN Research Group Lecture 2 Chair: Mark Haas Peter Boor: Pathomics and next generation pathology in IgAN and IgAVN |
11:50–13:00 Cubex A1 + A2 |
FREE COMMUNICATIONS Fabio Sallustio: Renal Progenitor Cells Can Modulate Inflammatory and Intestinal Immune Activation in IgA Nephropathy Ying Zheng: CX3CR1+ monocytes/macrophages promote regional immune injury in mesangial proliferative glomerulonephritis through crosstalk with activated mesangial cells Yuko Makita: Transglutaminase-2 specific IgA-producing plasma cells in experimental IgA nephropathy Selvin Sundar Raj Mani: Gut Microbiome in IgA Nephropathy: Associations with Baseline Disease Presentation and Longitudinal Clinical Outcomes in South Asians Yoshihito Nihei: Mucosal bacteria initiate production of anti-β2-spectrin IgA autoantibody through a mechanism of molecular mimicry Francesca Zanoni: Polygenic Risk Score Predicts IgA Nephropathy Recurrence and Graft Failure in Kidney Transplant Recipients Fabio Sallustio: MBL2 Deficiency and Graft Survival in Transplant Patients with IgA Nephropathy: Is Complement Inhibition Always Beneficial? |
13:00–14:00 Cubex A1 + A2 |
Lunch & INDUSTRY SYMPOSIUM |
14:00–15:00 Cubex A1 + A2 |
PLENARY SESSION 6: Treatment 1 Chairs: Daniel Cattran, Vladimir Tesar Jürgen Floege: What do the KDIGO Guidelines NOT tell us? Richard Lafayette: Who should we treat? Sydney Chi Wai Tang: How best to manage CKD in IgAN? |
15:00–15:30 Cubex A1 + A2 |
FREE COMMUNICATIONS Linlin Xu: Unveiling Genetic Determinants of Steroid Responsiveness in IgA Nephropathy: A TESTING Cohort Study David L. Hölscher: Pathomics-based estimation of treatment effects for corticosteroids in IgAN Xujie Zhou: Genome-wide association study meta-analysis reveals 50 susceptibility loci for IgA nephropathy and identifies B-cell receptor signaling to NF-κB pathway as a potential therapeutic target |
15:30–16:00 |
Coffee break |
16:00–17:00 Cubex A3 |
MODERATED POSTER SESSION Moderator: Kerstin Ebefors Meijun Si: Revealing the Spatial Structure of IgA Immune Complexes in IgA Nephropathy Using Volume Electron Microscopy Stacy D. Hall: Complement C3: A necessary component of pathogenic IgA1-containing immune complexes in IgA nephropathy Zhenhai Zhang: Functional characterization of a novel anti-Gd-IgA1 autoantibody P4 in IgA nephropathy pathogenesis Tibor Schomber: Effects of anti-APRIL antibody treatment versus dual APRIL/BAFF inhibition and anti-BAFF antibody treatment in wild type mice Jan Novak: In vivo evidence that mesangioproliferative activity of IgA1-IgG immune complexes in IgA nephropathy requires complement C3 and can be prevented by a protein tyrosine kinase inhibitor Colin Reily: NF-kB inhibitor increases production of galactose-deficient IgA1 and modulates activation of multiple transcription factors in several subpopulations of EBV-immortalized B cells from IgAN patients and healthy controls Chee Kay Cheung: Urinary biomarker analysis reveals rapid intrarenal anti-inflammatory and anti-fibrotic effects of sparsentan in IgA nephropathy in the SPARTAN study Kirk J. Rowley: Targeting APRIL and BAFF pathways: Divergent effects on immune populations and protective immunity, with implications for IgAN management Jicheng Lv: PEGylated Clostridium ramosum IgA protease clears both circulating and deposited IgA1 as a potential disease-modifying therapy for IgA nephropathy Kazuaki Mori: Sparsentan decreases mesangial IgA deposition in gddY mice; a possible role for mesangial-cell- surface autoantigen expression
Alexandra Audemard-Verger: Recommendations on diagnosis and treatment of adult-onset IgA Vasculitis proposed by the European IgA Vasculitis Study Group: focus on kidney involvement Zhiqiang Du: Preclinical and phase I clinical study of RG002C0106: a GalNAc-siRNA conjugate for complement-related glomerular diseases Federica Papadia: Epidemiological and Prognostic Insights into IgA Nephropathy: A Regional Cohort Study from Southern Italy Selvin Sundar Raj Mani: Baseline and Longitudinal Associations between serum C3/C4 levels and tissue complement biomarkers and IgA Nephropathy in South Asia Nobuo Tsuboi: Prognostic Significance of Persistent Hematuria in Japanese Patients with IgA Nephropathy: Findings from the Japan IgA Nephropathy Prospective Cohort Study (J-IGACS) Hiroyuki Ueda: Prognostic impact of proteinuria recurrence in IgA nephropathy: A post hoc analysis of the Japan IgA Nephropathy Prospective Cohort Study (J-IGACS) Shinya Yokote: Prognosis of Elderly Patients with IgA Nephropathy: A Post Hoc Analysis of the Japan IgA Nephropathy Prospective Cohort Study (J-IGACS) Dita Maixnerova: Intercontinental survey of patients with IgA nephropathy – preliminary analysis Keiichi Matsuzaki: Clinical Remission in IgA Nephropathy : Visualization of transition patterns and identification of an appropriate time point for prognostic assessment Eyal Rahmani: Long-Term Outcomes in IgA Nephropathy: Findings from the ERKNet Patient Registry (ERKReg)
Xujie Zhou: Causal Relationships Between Gut Microbiota and IgA Nephropathy: Evidence from Mendelian Randomization and Microbiome Validation Benedetta De Ponte Conti: Investigation of gut-derived immune cell in IgA nephropathy Fengtao Cai: Proteomics Unveils Molecular Profiles and Potential Pathogenic Mechanisms in IgA Nephropathy Jacqueline Haller: Association of Urinary Inflammatory Biomarkers with Disease Activity and Progression Risk in IgAN and IgAVN: Findings from a Single-Center Cohort Hannes Olauson: Renal and circulating Klotho levels in patients with IgA nephropathy Joshua Strzalka: Soluble Fcγ receptor ectodomains as inhibitors of FcγR activation in immune complex-mediated diseases Karin Bergen: Lower urine epidermal growth factor to monocyte chemoattractant protein 1 ratio is associated with elevated biomarkers of endothelial dysfunction in IgA nephropathy Jangwook Lee: Age- and Sex-Specific Gut Microbiome Alterations in IgA Nephropathy: Implications for Disease Pathogenesis and Progression Karin Bergen: Plasma endothelial biomarkers in relation to albuminuria, kidney function and CKD progression in IgA-nephropathy (encore from 62nd ERA congress) Yudai Tsuji: Comparative proteomic analysis of glomeruli and circulating IgA-immune complexes in IgA nephropathy
Shu Qu: Genetic regulation and therapeutic targeting of MTMR3 reshape TLR9-mediated IgA responses Sho Hamaguchi: Deep shotgun metagenomic analysis of the oral microbiome identifies extrachromosomal mobile genetic elements associated with IgA nephropathy Cheng-Hsu Chen: The Genetic Study Identifies Susceptibility Loci for IgA Nephropathy Francesca Annese: Molecular endophenotyping of IgA Nephropathy patients reveals immune-driven subgroups with distinct clinical outcomes Amandine Badie: The role of sCD89 myeloid receptor in glomerular hypercellularity in childhood IgA nephropathy Ming Li: The effects of multi-locus interaction on IgA nephropathy in Han Chinese population Filippo Azzali: Engineering of IgA-specific CARs for CAR-T cell therapy against IgA nephropathy Connor Hebborn: Evaluation of inhibitory oligotherapy for modulation of IgA expression Mayuko Kawabe: Tonsillar Immune Signatures in IgA Nephropathy: Elevated KLRG1 and ZBTB16 Expression in Germinal Center Regions Kerstin Ebefors: Activation of mesangial cells via phagocytosis in IgA nephropathy |
18:00–22:00 |
Conference Dinner |
Last update on 27 August 2025.
The programme might be subject to necessary changes.